ABSTRACT
Myeloproliferative neoplasms (MPNs) are a clonal disease of myeloid stem cells that are characterized by myeloid cell proliferation, bone marrow (BM) fibrosis, and symptoms associated with the accompanying peripheral blood cell abnormalities. The World Health Organization (WHO) provides diagnostic criteria for the following MPN subtypes: chronic myelogenous leukemia; BCR-ABL1-positive; polycythemia vera (PV); essential thrombocythemia (ET); primary myelofibrosis (PMF); chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; mastocytosis; and MPN-unclassifiable (MPN-U). 1 Common molecular events in MPNs are the V617F mutation in the JAK2 gene, mutations of exon 10 of the MPL gene (mainly involving codon W515), and JAK2 mutations on exon 12, which are included as one of the diagnostic criteria. [1] [2] [3] [4] Recently, novel frameshift mutations in exon 9 of the calreticulin (CALR) gene were found using next-generation sequencing in patients with JAK2 or MPL nonmutated PMF and ET. 5, 6 In these studies, CALR mutations were detected in approximately 20% to 25% of patients with ET and PMF and not in patients with PV. Most CALR mutations were deletions and insertions in exon 9, which cause frameshift mutations. The type 1 (L367fs*46) mutation, which results from a 52-base pair (bp) deletion, is found in approximately 50% of patients with CALR mutations, and the type 2 (K385fs*47) mutation, which results from a 5-bp TTGTC insertion, accounts for approximately 30% of patients with CALR mutations. [5] [6] [7] [8] [9] In patients with ET, CALR mutations have been associated with a lower hemoglobin level, lower leukocyte count, higher platelet count, and relatively low thrombotic risk. [9] [10] [11] In this study, we investigated the mutation profiles of CALR, JAK2, and MPL mutations in four different MPN subtypes in Korean patients with PMF, ET, PV, and MPN-U. In addition, we investigated the mutation profile of patients with acute panmyelosis with myelofibrosis (APMF), which is a very rare acute myeloid leukemia (AML) subtype characterized by diffuse myelofibrosis and increased blasts of 20% or more. The BM histologic features of APMF are sometimes indistinguishable from the acute MPN phase, thus blurring a common distinction. We performed a correlation analysis of mutation patterns with clinical, hematologic, and cytogenetic characteristics and prognostic impacts.
Materials and Methods

Patients
A series of 199 patients who were diagnosed with MPN and treated at Seoul National University Hospital were included in this study. The inclusion criteria for this study were the availability of BM samples collected at the time of diagnosis or revisit coupled with symptom aggregation after a follow-up period. MPNs were strictly diagnosed according to the 2008 WHO classification criteria. 1 Patients were diagnosed with the following subtypes: 54 PMF, 79 ET, 58 PV, and eight MPN-U. Eight patients with MPN-U had panmyelosis without diffuse fibrosis; therefore, the prefibrotic stage of PMF, ET, or PV could not be determined. In addition, four patients with APMF who had blast increase and diffuse fibrosis were included in this study. The following laboratory and clinical information was obtained for each patient: dates of diagnosis and therapy initiation, age, sex, ethnicity, hemoglobin levels, platelet count, conventional G-banding cytogenetic analyses of BM cells, and the presence of splenomegaly. For patients with PMF, the Dynamic International Prognostic Scoring System-plus (DIPSS-plus) risk categorizations were assessed as previously described. 12 This study complied with Declaration of Helsinki. All BM samples were collected with informed consent, and the study was reviewed and approved by the Institutional Review Board of Seoul National University College of Medicine.
BM Histologic Examination
Hematopathologists (S.Y.K. and D.S.L.) reviewed Wright-Giemsa-stained BM smears and H&E-stained sections of the BM trephine biopsy specimens. In all patients, immunohistochemical staining was performed for reticulin, collagen, CD34, CD117, and CD61 using BM sections (all from Dako, Glostrup, Denmark). BM fibrosis (MF) was assessed according to the European consensus grading system on a scale of MF-0 to MF-3. 13 
Cytogenetic Analysis
Cytogenetic studies using standard G-banding techniques on heparinized BM samples were performed as part of the diagnostic workup. At least 20 metaphases were analyzed whenever possible. Clonal abnormalities were defined as two or more cells with the same chromosomal gain or structural rearrangement or at least three cells with the same chromosome deletion. Karyotypes were recorded according to the International System for Human Cytogenetic Nomenclature (ISCN) 2013. 14 In addition, fluorescence in situ hybridization (FISH) was performed in most cases (n = 158). The following commercial FISH probes were used in subset of patients: a BCR/ ABL dual-color, dual-translocation probe (n = 158); the 13q14 SpectrumOrange probe (n = 66); the LSI D20S108 (20q12) probe (n = 77); the LSI EGR1 (5q31) probe (n = 27); the LSI D7S522 (7q31) probe (n = 18); the CEP 8 probe (n = 23); and the LSI 1p32/1q25 probe (n = 21) (all from Abbott Molecular, Des Plaines, IL). Slides were stained with FISH probes and counterstained with DAPI, and the fluorescence signals were analyzed by fluorescent microscopy (Zeiss, Göttingen, Germany). FISH results were recorded according to the ISCN 2013. 14 
DNA Extraction and Detection of Mutations Using Sanger Sequencing
Genomic DNA was extracted from frozen BM mononuclear cells of all patients. DNA was extracted using the MagNA Pure LC DNA Isolation Kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer's instructions. DNA quality was analyzed by assessing the 260/280 absorbance ratio using an ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).
The following primers were used for polymerase chain reaction (PCR) amplification of the CALR, JAK2, and MPL genes: CALR forward, 5′-CAT TCA TCC TCC AGG TCA  AG-3′; CALR reverse, 5′-AGG GGA ACA AAA CCA  AAA TC-3′; JAK2 exon 14 forward, 5′-TCC TCA GAA  CGT TGA TGG CA-3′; JAK2 exon 14 reverse, 5′-ATT GCT TTC CTT TTT CAC AA-3′; JAK2 exon 12 forward, 5′-CTC  CTC TTT GGA GCA ATT CA-3′; JAK2 exon 12 reverse,  5′-CCA ATG TCA CAT GAA TGT AA-3′ ; MPL forward, 5′-TGG GCC GAA GTC TGA CCC TTT-3′; and MPL reverse, 5′-ACA GAG CGA ACC AAG AAT GCC TGT-3′. The amplified 537-bp, 453-bp, 280-bp, and 212-bp fragments covered CALR exons 8 and 9, the JAK2 V617F site in exon 14, JAK2 exon 12, and exon 10 of MPL, respectively. PCR was performed using 25 to 100 ng genomic DNA in 100 µL PCR solution (10 µL of 10× MG Taq-HF buffer, 0.2 µmol/L of each primer, 10 µL of 2 mmol/L MG dNTPs mixture, 1 µL of MG Taq-HF polymerase [Macrogen, Seoul, Korea], and distilled water). The PCR used the following cycle protocol: an initial 5-minute denaturation step at 94°C followed by 35 cycles of 94°C for 30 seconds, 58°C to 64°C for 30 seconds (depending on the primers), and 72°C for 60 seconds, with a final 7-minute extension at 72°C. The PCR products were purified and sequenced using a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA) and an ABI 3730 XL automatic sequencer (Applied Biosystems) using the above-described primers.
Statistical Analysis
Fisher exact test and the χ 2 test were used to compare categorical variables, and the Mann-Whitney U test was used for continuous variables. Overall and leukemia-free survival were estimated using the Kaplan-Meier method, and differences between the survival curves were analyzed using the log-rank test. Statistical analyses were performed using SPSS version 17.0 (SPSS, Chicago, IL). P values less than .05 were considered statistically significant.
Results
Clinical Characteristics of Enrolled Patients
The baseline characteristics of all patients are summarized in ❚Table 1❚. All patients were Korean, with a median age of 58 years (range, 8-84 years). There were 91 (46%) male and 108 female patients. Hemoglobin, leukocyte, and platelet counts were variable among the different disease subtypes. Twenty-one (10.6%) patients progressed to the 
CALR and Other Mutations
In the 199 patients with MPN, CALR frameshift mutations were detected in 25 (12.6%) ❚Table 2❚. JAK2 V617F mutations were detected in 134 patients (67.3%), and mutations in JAK2 exon 12 were detected in two (1.0%) patients with PV. MPL was detected in seven (3.5%) patients (six patients with the MPL W515L mutation and one patient with the MPL W515K mutation). Thirty-six (18.1%) patients were triple negative for all three mutations. CALR frameshift mutations and JAK2 or MPL mutations were mutually exclusive. Among those patients without JAK2 or MPL mutations (n = 57), the frequency of CALR frameshift mutations was 43.9%. Among the CALR frameshift mutations, 15 patients had typical type 1 mutations (L367fs*46), and nine patients had type 2 mutations (K385fs*47). One patient had slightly different breakpoints and subsequent amino acid products (L367fs*49; c.1093-1138del) with typical type 1 deletions (c.1092_1143del). In the disease subgroups, CALR frameshift mutations were detected in eight (14.8%) patients with PMF and 14 (17.7%) patients with ET. JAK2 mutations were observed in 57.4% and 63.3% of patients with PMF and ET, respectively. No patients with PV had a CALR frameshift mutation, but JAK2 mutations were found in 91.4% of patients with PV. In all four patients with APMF, no mutations in the JAK2, CALR, and MPL genes were observed. Among the eight patients with MPN-U, three (37.5%) had a CALR frameshift mutation, which is a significantly higher ratio of CALR/JAK2 mutations compared with the PMF and ET groups (3/2 vs 22/81, P = .045).
CALR Mutations and Correlation With Clinical Characteristics
In patients with PMF, CALR frameshift mutations were associated with lower levels of leukocytes and absolute neutrophils, less significant BM hypercellularity, and a higher number of BM megakaryocytes compared with patients with JAK2 mutations ❚Table 3❚. The transfusion requirement decreased in patients with CALR mutations patients compared with patients with JAK2 mutations (P = .066). No patients progressed to accelerated or blast phase, and no significant thrombotic events were observed in patients with PMF who had CALR mutations, although a statistical comparison was difficult because of the small number of events in the JAK2-mutated groups (progression to accelerated or blast phase [25.8%] and thrombotic events [16.1%] for patients with PMF who had JAK2 mutations).
In patients with ET, patients with CALR frameshift mutations had lower hemoglobin levels and leukocyte and granulocyte counts and tended to have higher platelet counts ❚Table 4❚. In addition, patients with ET who had CALR mutations more frequently progressed to accelerated or blast phase disease compared with patients with a JAK2 mutation, but the number of patients was small (n = 3 [21.4%]; P = .032). There were slightly higher rates of male patients (50%) among patients with ET who had CALR mutations compared with patients with JAK2 mutations (30%); however, there was no statistical significance between these groups (P = .164). Patients with ET who had CALR mutations had slightly higher ratios of progression to post-ET myelofibrosis than did patients with JAK2 mutations, but this difference was not statistically significant (21.4% vs 14.0%, P = .499).
CALR Mutations and Their Correlation With Cytogenetic Characteristics
Cytogenetic abnormalities assessed by G-banding analysis were observed in 21 (38.9%) patients with PMF and seven (8.9%) patients with ET. Three patients with CALR mutations had cytogenetic abnormalities. There were no significant differences in the percentages of patients with cytogenetic abnormalities between those with JAK2 and CALR mutations (Tables 3 and 4 ; PMF, 35.5% vs 25.0%, P = .575; ET, 12.0% vs 7.1%, P = .607). CALR frameshift mutations were not associated with any specific cytogenetic abnormalities. Two patients with PMF who had cytogenetic abnormalities had 46,XY,del(20)(q11.2) [20] and 47,XY,+der(1;19)(q10;p10) [13] /46,XY [7] mutations. One patient with a del(20)(q11.2) mutation also had deletions on 20q in 73.5% of cells by interphase FISH analysis. One patient with ET had complex abnormalities (44,XX,der(1)t(1;?3)(p36;q23),der(3;12) ( q 1 0 ; q 1 0 ) , − 5 , a d d ( 1 9 ) [3] ) and was tested for cytogenetic abnormalities after progression to the accelerated phase with 9.7% of blasts in BM. Sequential interphase FISH analyses revealed 51.5% cells with 5q deletions in the accelerated phase and 97.0% cells with 5q deletions in the subsequent blast phase.
CALR Mutations and Their Prognostic Significance
When the overall and leukemia-free survivals were compared among patients with CALR, JAK2, and MPL mutations and triple-negative patients, no significant differences were detected between patients with PMF and ET ❚Figure 1❚. However, in patients with PMF, those with CALR mutations seemed to have better overall and leukemia-free survival compared with patients with JAK2 mutations (P = .264 and P = .320). However, the small number of patients made it difficult to reach conclusive results ( Figures 1A and 1B) . 
Comparison of Clinical and Laboratory Characteristics of Type 1 and Type 2 CALR Mutations
Type 1 CALR mutations were present in six patients with PMF and nine patients with ET, and type 2 CALR mutations were present in two patients with PMF and five patients with ET; therefore, there were no significant differences between the distribution of type 1 and type 2 mutations among the MPN subtypes ❚Table 5❚. Because of the small number of patients belonging to specific MPN subtypes with different types of CALR mutations, we compared the clinical and laboratory characteristics of the type 1 and type 2 CALR mutations among the total group of patients with MPN. Patients with type 2 mutations had slightly higher hemoglobin levels and blast counts in BM (Table 5 ). Patients with type 1 mutations tended to develop more fibrosis than did patients with type 2 mutations (56.3% vs 22.2%, respectively, P = .099). In addition, patients with type 2 mutations had a slightly younger median age (type 2 vs type 1, 48.8 vs 59.8 years, respectively; P = .174) and slightly higher median platelet counts (1,081 × 10 9 /L vs 763 × 10 9 /L, respectively; P = .074), but these differences were not statistically significant, likely due to the small sample size. There were no significant differences in overall survival between patients with type 1 and type 2 mutations (P = .940). When the prognoses of type 1 and type 2 CALR mutations were compared among the patients with PMF, the patients with type 1 mutations appeared to show better overall and leukemia-free survival rates compared with the patients with type 2 mutations, although this difference was not statistically significant because of the small sample size (P = .307 and P = .341) ❚Figure 2A❚ and ❚Figure 2B❚. Among the ET patient group, no significant differences in overall or leukemia-free survivals were detected between the patients with type 1 and type 2 CALR mutations ❚Figure 2C❚ and ❚Figure 2D❚.
Discussion
In this study, we also observed frequent (43.9%) CALR mutations in patients with PMF, ET, and MPN-U without JAK2 and MPL mutations but not in patients with PV without JAK2 and MPL mutations, and these findings are consistent with previous reports. 5, 6, 15, 16 Previous studies of FLT3 mutations among Korean patients with AML have reported significantly lower mutation frequencies compared with reports of other Asian and Western patients. 17, 18 Our data and a previous study of Chinese patients with ET demonstrated no significant difference in CALR mutation frequency compared with Western studies. 15 Therefore, there may be no significant ethnic influences in the occurrence of CALR mutations. Interestingly, in this study, CALR mutations were most frequent in patients with MPN-U (37.5%) compared with mutations in the PMF and ET groups (14.8% and 17.7%, respectively). We noticed that CALR mutations were absent in patients with APMF, in whom a differential diagnosis of MPN in blast phase was difficult. Although this study included a small number of patients, we observed that APMF had different pathogenetic mechanisms compared with MPNs, although the disease presentation may be similar in many aspects. When we compared the clinical and hematologic characteristics of patients with CALR mutations and those patients with JAK2 mutations, patients with PMF who had CALR mutations had lower levels of leukocytosis, lower neutrophilia levels, and higher megakaryocyte burden. A previous study found that CALR mutations were associated with a younger age, higher platelet count, lower thrombosis risk, lower DIPSS-plus score, and less leukocytosis and were less likely to be transfusion dependent. 16 Our data for patients with CALR mutations also showed a tendency of higher platelet counts and lessened transfusion requirement, although these differences were not statistically significant, likely due to a small sample size. No overt tendency for a younger age in patients with PMF who had CALR mutations was evident in our study. In patients with ET, CALR mutations were associated with lower levels of leukocytosis, lower hemoglobin levels, and higher platelet counts, which were compatible with previous reports examining overall characteristics. 10, 11 Previous studies have also reported that patients with CALR mutations were preferentially male and younger in age. 10, 11 We also observed a preference for males in this group; however, there were no differences in age between the patients with CALR and JAK2 mutations. When we investigated the prognostic relevance of CALR mutations, patients with PMF who had CALR mutations seemed to have a better prognosis, although this observation was difficult to confirm because of the small sample size. Most current data have also indicated that the CALR-mutated group may have a favorable prognosis compared with patients with JAK2 mutations and those with triple-negative PMF. 16, 19 Consistent with this observation, the patients with PMF who had CALR mutations in this study had lower rates of progression to accelerated or blast phase and a lower incidence of thrombotic events, although the statistical significance was difficult to determine because of the small numbers of events. In ET, the prognostic significance of a CALR mutation is not certain. One study suggested that the CALR mutations conferred a survival advantage in patients with ET 6 ; however, subsequent studies have presented similar long-term survival rates between patients with ET who had JAK2 and CALR mutations. 10, 11, 15, 20 Previous studies have suggested a longer thrombosis-free survival 10, 11, 21 and similar leukemia transformation rates 20 for CALR-mutated ET. In this study, we also did not observe significant differences in overall survival between patients with ET who had CALR and JAK2 mutations. However, we observed three (21.4%) patients with ET who progressed to accelerated or blast phase in the CALR-mutated group. Because transformation to acute leukemia in patients with ET is a rare event, this observation is a substantially notable frequency, but prognostic significance was not observed. The high rate of progression may be due to the possible misclassification of patients with "PMF in early fibrotic stage" to ET because of the lower leukocyte counts, higher platelet counts, and higher megakaryocyte burden. However, with the current diagnostic system largely depending on morphologic and hematologic features, these differences may be difficult to discriminate. In addition, although the CALR-mutated group may be considered a lower-risk group with the current observations, the risk for leukemic transformation needs to be carefully assessed in combination with other factors. Therefore, the prognostic significance of CALR could be different among the MPN categories.
Notably, CALR mutations were the most frequent in patients with MPN-U. MPN-U is a disease entity that has definite MPN features but fails to meet the criteria for any of the specific MPN entities or has features that overlap two or more of the MPN categories. Among the eight patients with MPN-U, three showed a CALR mutation, which confounded the discrimination of ET and early PMF. In a sense, MPN-U has an overlapping spectrum among MPN subtypes within the WHO classification. These overlapping features resulted in the highest frequency of CALR mutations in the MPN-U group among the MPN categories. Classification of MPNs based on molecular characteristics would help to reduce ambiguity in the diagnosis of the WHO MPN subtypes.
CALR is a Ca 2+ -binding protein chaperone that is primarily localized to the endoplasmic reticulum 22 and is located on 19p13.2. The calreticulin protein has three domains, including an amino terminal N-domain, central proline-rich P-domain, and carboxyl terminal C-domain. 16 The function of calreticulin involves Ca 2+ homeostasis, disposal of misfolded proteins, cell adhesion, and immune responses. 23 Most CALR mutations involve deletions and insertions in the C-domain, which cause frameshift mutations and are classified into type 1 and type 2 mutations. Previous studies have shown higher platelet counts and lower hemoglobin and leukocyte counts for patients with type 1 and type 2 mutations compared with patients with JAK2 mutations, and in patients with ET, male sex and a younger age have been associated with type 1 and type 2 variants, respectively. 7 In addition, platelet counts are higher in patients with type 2 mutations compared with those with type 1 mutations. 7 In patients with PMF, a comparison of type 2 CALR and JAK2 mutations showed more similarities than differences, and a comparison of type 1 and type 2 CALR mutations showed that the latter were associated with higher DIPSS-plus risk ❚Figure 2❚ Prognosis of primary myelofibrosis (PMF) (A, B) and essential thrombocythemia (ET) (C, D) according to presence of type 1 and type 2 CALR mutations and JAK2 mutation. Overall survival (A) and leukemia-free survival (B) of patients with PMF according to the presence of type 1 and type 2 CALR and JAK2 mutation. Overall survival (C) and leukemia-free survival (D) of patients with ET according to the presence of type 1 and type 2 CALR and JAK2 mutations. © American Society for Clinical Pathology scores, leukocytosis, increased peripheral blood percentages, and decreased survival. 8 Although our patient cohort was too small for a complete analysis, the patients with type 2 CALR mutations in our study had slightly higher platelet levels and higher blast counts in BM and tended to be younger.
The limitations of this study are the small number of patients, the retrospective nature of the study, and an analysis involving a single center. An additional prospective multicenter study should be performed to allow a more comprehensive genetic analysis and to assess the prognostic significance in Korean patients with PMF.
In conclusion, we observed consistent mutation frequencies and clinical characteristics in Korean patients with MPN. The CALR mutation was most frequent in patients with MPN-U. The CALR mutation was associated with progression to accelerated or blast phase in ET, but the overall survival was superior (not statistically significant) in CALRmutated PMF. Therefore, the clinical significance of CALR mutations is different among MPN subtypes and still needs further study, specifically addressing it in the context of the MPN disease stages.
